Calcilytix Therapeutics, Inc., a BridgeBio company | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism	endocrine system disorder, hypoparathyroidism, parathyroid gland disorder	Recruiting	Phase 3	2026-09-16		NCT07805356
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1	Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hypercalciuria, Hypercalciuric Hypocalcemia, Familial, Hypocalcemia, Male Urogenital Diseases, Musculoskeletal Abnormalities, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urological Manifestations, Water-Electrolyte Imbalance, calcinosis, calcium metabolic disease, endocrine system disorder, hypoparathyroidism, kidney disorder, metabolic disease, muscle tissue disorder, musculoskeletal system disorder, nephrocalcinosis, nephrolithiasis, nervous system disorder, neuromuscular disease, parathyroid gland disorder, urinary system disorder, urolithiasis	Active, not recruiting	Phase 3	2026-07-29		NCT05680818
ADH1 and ADH2 Disease Monitoring Study (DMS)	Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hypercalciuria, Hypercalciuric Hypocalcemia, Familial, Hypocalcemia, Male Urogenital Diseases, Musculoskeletal Abnormalities, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urological Manifestations, Water-Electrolyte Imbalance, autosomal dominant hypocalcemia, calcinosis, calcium metabolic disease, endocrine system disorder, hypoparathyroidism, kidney disorder, metabolic disease, muscle tissue disorder, musculoskeletal system disorder, nephrocalcinosis, nephrolithiasis, nervous system disorder, neuromuscular disease, parathyroid gland disorder, urinary system disorder, urolithiasis	Active, not recruiting	Not stated	2026-04-30		NCT05227287
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)	Autosomal Dominant Hypocalcemia Type 1 (ADH1)	Recruiting	Phase 2 / Phase 3	2026-04-22		NCT07080385